Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
📈 Do SIJ lesions progress in #axSpA?
DESIR cohort (n=649, 10yrs):
Yes, slowly, but bDMARDs reduce erosion progression
#OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🔍 Best imaging outcome for #axSpA structural change?
SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change
#OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA?
COPECARE (n=25, 1yr): sCT matches ldCT with no radiation
#OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🔍 Is #axSpA overdiagnosed locally?
IMPROVE-axSpA prosp study (n=969):
Yes!
Only 54% locally confirmed centrally
#OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🔍Can early TNFi beat step-up csDMARDs in pSpA?
SPARTACUS RCT (n=97) says YES
60% vs 33% remission at 24 wks
#EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
💉 IXE+TZP beat IXE alone in obese PsA?
YES - TOGETHER-PsA RCT
33.5% vs 20.4% ACR50 at week 36 in 271 patients
OP069 #EULAR2026 @RheumNow
@DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
🥗 Does diet improve PsA?
DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts
Weight loss drove outcomes
OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ
sheila RHEUMarampa
1 week 2 days ago
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts
Males ⬆️rate of xray prog(msasss)
Sex diffs exist in SpA
Need for sex-specific mgt
AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 2 days ago
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
